Nasdaq-listed BioNTech, which is testing a COVID-19 vaccine candidate, said Monday it raised $250 million from Singapore state-owned investment company Temasek Holdings and other accredited investors in a private placement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
